Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor ProgramBusiness Wire • 09/29/22
FORMA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTXBusiness Wire • 09/27/22
Carmot Therapeutics Announces Significant Leadership Team Expansion with Anne Phillips, MD, FRCPC Previously SVP Novo Nordisk, Joining the Board of Directors and Heather Turner, J.D. Joining as COOBusiness Wire • 09/21/22
Novo Nordisk and Microsoft collaborate to accelerate drug discovery and development using big data and artificial intelligenceGlobeNewsWire • 09/12/22
FORMA THERAPEUTICS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTXBusiness Wire • 09/02/22
Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics BuyoutInvestors Business Daily • 09/01/22
Forma Therapeutics to be acquired by Novo Nordisk in a cash deal valued at $1.1 billionMarket Watch • 09/01/22
Novo Nordisk: Assessing Hype Towards Obesity Care Following The Q2 Results Drop, Story Is IntactSeeking Alpha • 08/23/22
Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetesGlobeNewsWire • 08/22/22
Novo Nordisk A/S (NVO) CEO Lars Fruergaard Joergensen on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/04/22
Novo Nordisk's Obesity Sales Nearly Doubled, But That Wasn't Enough For NVO StockInvestors Business Daily • 08/03/22